Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | MMP9 | P14780 | 4/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074962 | 0.82 | PLCG1 (0.53) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2779200 | 0.81 | ALDH1A1 (0.57) | CA2KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10258225 | 0.80 | PLCG1 (0.55) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL10266897 | 0.80 | PLCG1 (0.55) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL11951567 | 0.79 | GAA (0.46) | CA2MMP13MMP1MMP2MMP9 | |
| SCHEMBL4010614 | 0.79 | CA1 (0.49) | CA2KMT2AMMP13MMP1MMP2 | |
| SCHEMBL4873168 | 0.79 | GAA (0.61) | CA2KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2923150 | 0.79 | CA2 (0.52) | CA2KMT2AMMP13MMP1MMP2 | |
| SCHEMBL3067678 | 0.79 | MMP13 (0.42) | PLCG1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL778303 | 0.78 | PSIP1 (0.60) | KMT2ACYP1A2CYP2C19TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016071293-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2016-05-12 | — | — | WO | disclosed |
| US-20120218878-A1 | Objective Lens, Optical Pickup Apparatus, and Optical Information Recording Reproducing Apparatus | KONICA MINOLTA OPTO, INC. (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2428953-A1 | OBJECTIVE, OPTICAL PICK-UP DEVICE, AND OPTICAL INFORMATION RECORDING/REPRODUCING DEVICE | Konica Minolta Opto, Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-8068749-B2 | Fixing apparatus and image forming apparatus provided with fixing apparatus | SHARP KABUSHIKI KAISHA (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110183412-A1 | ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS | Facet Biotech Corpration (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | disclosed |
| EP-2074086-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080119966-A1 | Wireless Sensing and Communication System for Traffic Lanes | INTELLIGENT TECHNOLOGIES INTERNATIONAL, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008048609-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1494972-B1 | METHOD FOR TREATING WASTE STREAMS | EAU VIRON INC (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | PLCG1 2861/4885CA2 2621/4885KMT2A 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.